Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Acute in vivo resistance in high-dose therapy.

Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E 3rd.

Clin Cancer Res. 1998 Feb;4(2):483-91.

2.

Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.

Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS.

In Vivo. 1997 Nov-Dec;11(6):463-72.

PMID:
9509296
3.

Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin.

Teicher BA, Maehara Y, Kakeji Y, Ara G, Keyes SR, Wong J, Herbst R.

Int J Cancer. 1997 Mar 28;71(1):49-58.

4.

Lisofylline as a modifier of radiation therapy.

Wong JS, Ara G, Keyes SR, Herbst R, Coleman CN, Teicher BA.

Oncol Res. 1996;8(12):513-8.

PMID:
9160355
5.

Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin.

Sartorelli AC, Belcourt MF, Hodnick WF, Keyes SR, Pritsos CA, Rockwell S.

Adv Enzyme Regul. 1995;35:117-30.

PMID:
7572339
6.

Porfiromycin as an adjunct to radiotherapy in young and old mice.

Rockwell S, Hughes CS, Keyes SR, Sartorelli AC, Kennedy KA.

Exp Gerontol. 1993 May-Jun;28(3):281-93.

PMID:
8344398
7.

Isolation, identification, and assay of [3H]-porfiromycin adducts of EMT6 mouse mammary tumor cell DNA: effects of hypoxia and dicumarol on adduct patterns.

Tomasz M, Hughes CS, Chowdary D, Keyes SR, Lipman R, Sartorelli AC, Rockwell S.

Cancer Commun. 1991 Jul;3(7):213-23.

PMID:
1714285
8.

Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo.

Rockwell S, Keyes SR, Loomis R, Kelley M, Vyas DM, Wong H, Doyle TW, Sartorelli AC.

Cancer Commun. 1991 Jun;3(6):191-8.

PMID:
2049227
9.

Distribution of porfiromycin in EMT6 solid tumors and normal tissues of BALB/c mice.

Keyes SR, Rockwell S, Kennedy KA, Sartorelli AC.

J Natl Cancer Inst. 1991 May 1;83(9):632-7.

PMID:
2023281
10.

Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells.

Keyes SR, Loomis R, DiGiovanna MP, Pritsos CA, Rockwell S, Sartorelli AC.

Cancer Commun. 1991;3(10-11):351-6.

PMID:
1760250
11.

Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues.

Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE.

Cancer Res. 1989 Nov 15;49(22):6275-9.

12.

Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.

Pritsos CA, Keyes SR, Sartorelli AC.

Cancer Biochem Biophys. 1989 Oct;10(4):289-98.

PMID:
2559790
13.

Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.

Rockwell S, Keyes SR, Sartorelli AC.

Anticancer Res. 1989 Jul-Aug;9(4):817-20.

PMID:
2479329
14.
15.

Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo.

Rockwell S, Keyes SR, Sartorelli AC.

Cancer Chemother Pharmacol. 1989;24(6):349-53.

PMID:
2477164
16.

Preclinical studies of porfiromycin as an adjunct to radiotherapy.

Rockwell S, Keyes SR, Sartorelli AC.

Radiat Res. 1988 Oct;116(1):100-13.

PMID:
3186923
17.

Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.

Rockwell S, Keyes SR, Sartorelli AC.

Cancer Res. 1988 Oct 1;48(19):5471-4.

18.

Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.

Keyes SR, Rockwell S, Sartorelli AC.

Cancer Res. 1987 Nov 1;47(21):5654-7.

19.

The effects of adriamycin on intracellular calcium concentrations of L1210 murine leukemia cells.

Keyes SR, Hickman JA, Sartorelli AC.

Eur J Cancer Clin Oncol. 1987 Mar;23(3):295-302.

PMID:
2439346
20.
21.

Differentiation of WEHI-3B D+ monomyelocytic leukemia cells by retinoic acid and aclacinomycin A.

Gamba-Vitalo C, Blair OC, Keyes SR, Sartorelli AC.

Cancer Res. 1986 Mar;46(3):1189-94.

22.
23.

Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.

Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC.

Adv Enzyme Regul. 1985;23:291-307.

PMID:
3934922
24.

Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.

Keyes SR, Rockwell S, Sartorelli AC.

Cancer Res. 1985 Jan;45(1):213-6.

25.

Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.

Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC.

Cancer Res. 1984 Dec;44(12 Pt 1):5638-43.

26.

Coupling of transmembrane proton gradients to platelet serotonin transport.

Keyes SR, Rudnick G.

J Biol Chem. 1982 Feb 10;257(3):1172-6.

27.

Biochemical properties of cytochrome b5-dependent microsomal fatty acid elongation and identification of products.

Keyes SR, Cinti DL.

J Biol Chem. 1980 Dec 10;255(23):11357-64. No abstract available.

28.

Rat liver microsomal elongation of fatty acids. Possible involvement of cytochrome b5.

Keyes SR, Alfano JA, Jansson I, Cinti DL.

J Biol Chem. 1979 Aug 25;254(16):7778-84. No abstract available.

29.
30.

Biochemical properties of rat liver mitochondrial aldehyde dehydrogenase with respect to oxidation of formaldehyde.

Cinti DL, Keyes SR, Lemelin MA, Denk H, Schenkman JB.

J Biol Chem. 1976 Mar 25;251(6):1571-7.

Supplemental Content

Loading ...
Support Center